Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma

Phase 2

Completed

• Conditions: Colorectal Cancer
• Interventions: Biological: G17DT-Irinotecan

• Registration Number: NCT02118064
• Lead Sponsor: Cancer Advances Inc.

Brief Summary

This study was designed to evaluate the ability for G17DT to slow or arrest tumor growth in patients with refractory colon cancer who had been previously treated with an Irinotecan-based chemotherapy.

Detailed Description

Not available

Study Timeline

• Study Start: 2001-03
• Primary Completion: 2002-12
• Status Verified: 2014-01
• Study First Submitted: 2014-04-16
• Study First Submitted QC: 2014-04-17
• Last Update Submitted: 2014-04-17
• Study First Posted: 2014-04-21
• Last Update Posted: 2014-04-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 161

Inclusion Criteria

• Have histologically confirmed cancer of the colon or rectum or both and objective evidence of distant metastases

• Have measurable disease

• Have previously been treated with an irinotecan based chemotherapy

• Have progressive metastatic disease after an irinotecan containing chemotherapy regimen (alone or in combination) for metastatic colorectal cancer

• Be at least 18 years of age

• Have laboratory data as specified below:

  • Aspartate aminotransferase (AST) and ALT less than 2.5 times upper limit of normal
  • Bilirubin less than 1.5 mg/dL (SI units, 25.65 mol/L)
  • Creatinine less than 1.5 mg/dL (SI units, 132 mol/L)
  • White blood cell (WBC) count greater than 3,000/mm3
  • Platelets greater than 100,000/mm3
  • Hemoglobin more than 9.5 g/dL (SI units, 5.9 mol/L)
  • International normalized ratio of prothrombin time less than 1.2, and activated partial thromboplastin time no more than 5 seconds above normal limits

• Have a life expectancy of at least 3 months

• Have a KPS score of 70 or greater

• Use contraceptive methods, if sexually active

• Have the ability to understand the requirements of the study, to provide written informed consent, agree to abide by the study restrictions, and agree to return for the required assessments

Exclusion Criteria

• Be pregnant or nursing
• Have only symptomatic locally recurrent colorectal cancer
• Have had any active cancer in addition to metastatic colorectal cancer within the last 5 years except curatively treated nonmelanomatous skin cancer
• Have received any prior anticancer immunotherapy
• Have central nervous system metastasis, whether treated or not
• Have bone metastases as sole manifestation of metastatic colorectal cancer
• Have received chemotherapy within the previous 21 days
• Have had major surgery within 21 days
• Have immunodeficiency (primary or acquired)
• Have undergone bone marrow transplantation within the last year
• Require chronic administration of corticosteroids; inhaled corticosteroids for asthma and chronic obstructive pulmonary disease are allowed
• Use in the past 30 days or concomitant use of immunosuppressants, including systemic (i.e., oral or injected) corticosteroids
• Have participated in any clinical trial involving conventional or investigational drugs or devices within 21 days before G17DT irinotecan administration
• Have contraindication to irinotecan based therapy
• Have hypersensitivity to diphtheria toxoid
• Use in the past 14 days or chronic concomitant use of proton pump inhibitors
• Have uncontrolled serious cardiovascular or metabolic disease or any other uncontrolled serious medical or psychiatric illness
• Have any condition that is likely to detrimentally affect regular follow up

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
G17DT-Irinotecan	G17DT-Irinotecan	500µg dose of G17DT intramuscular injection in combination with 125 mg/m\^2 intravenous infusion of Irinotecan over 90 minutes.

Primary Outcome Measures

Name	Time	Method
Survival time	up to 12 months	The vital status of patients was monitored until death or end of the study.
Number of Patients with Serious and Non-Serious Adverse Events	Up to 12 months	Adverse events, defined as any event involving adverse reactions, illnesses with onset during the study, or exacerbations of pre-existing illnesses, were assessed at each visit.
Tumor response	up to 12 months	Evaluate the effect of G17DT-Irinotecan combination therapy on tumor response assessed by magnetic resonance imaging or computed tomography.